Articles

Patent Docs: The Trans-Pacific Partnership--What it may mean for the pharmaceutical industry

While the treaty’s principal provisions include lower tariffs and dispute resolution mechanisms, there are several sections related to patent law relevant to the U.S. pharmaceutical industry, and Kevin Noonan explains
Written byKevin Noonan
| 3 min read

The Trans-Pacific Partnership (TPP), the latest in a series of multination international agreements (like the North American Free Trade Agreement (NAFTA) and the GATT/TRIPS agreements), is aimed at reducing trade barriers and promoting global free trade. It has been signed by representatives of 12 nations: Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, United States and Vietnam. The signatory countries (and perhaps other countries in the region that have evinced an interest in becoming signatories in future, such as Korea and China) are a growing part of the globe and are expected to comprise the world’s fastest growing market over the next 10 to 20 years. While the treaty’s principal provisions include lower tariffs and dispute resolution mechanisms, there are several sections related to patent law relevant to the U.S. pharmaceutical industry.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.